Central Lab Market Regional Analysis:
North America Market Insights
North America region is set to dominate around 40.6% market share by 2035. The high prevalence of infectious and chronic diseases, an increase in patient awareness about the significance of laboratory tests, increasing adoption of technological developments with proper quality, efficient and effective serve, and a significantly growing proportion of research and development in the region. For instance, medical and health research and development (R&D) investment in the United States reached approximately USD 244 billion in 2020, an 11% expansion from 2019.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of central lab is evaluated at USD 3.81 billion.
The global central lab market size exceeded USD 3.62 billion in 2025 and is set to expand at a CAGR of over 5.7%, surpassing USD 6.3 billion revenue by 2035.
North America’s central lab market will dominate over 40.6% share by 2035, driven by increased R&D spending and rising prevalence of chronic diseases.
Key players in the market include Laboratory Corporation of America Holdings (Labcorp), ICON Plc, Medpace, Inc., Eurofins Scientific (Ireland) Limited, LabConnect, Cerba Research NV, Frontage Laboratories, Inc., Lambda Therapeutic Research Limited, InVitro International (IVRO), Clinical Reference Laboratory, Inc.
